Kazia launches preclinical collaboration with QIMR Berghofer Medical Research Institute and announces patient filing

Kazia Therapeutics and Professor Sudha Rao are collaborating on a research project involving the use of the drug Paxalisib.

Daniela was given the opportunity to use Paxalisib as she had access to the drug through a compassionate use program, and was able to receive treatment in addition to the standard of care for her glioblastoma. The data Professor Sudha Rao is collecting from Daniela’s samples during treatment will help further understand the drug’s efficacy in treating the disease and potentially benefit future patients.

Click below for more the full announcement